Barclays has upgraded Agilent Technologies Inc (A) to Overweight from Equal-Weight, effective December 14, 2025. This decision underscores a more optimistic outlook on the company's prospects.
Agilent Technologies, headquartered in Santa Clara, California, operates in the Life Sciences Tools & Services sector. The firm employs approximately 18,000 full-time staff and provides application-focused solutions across various markets, including life sciences, diagnostics, and applied chemicals. Its segments encompass Life Sciences and Diagnostics Markets, Agilent CrossLab, and Applied Markets.
As of December 11, 2025, Agilent Technologies boasts a market capitalisation of $40.6 billion, a price-to-earnings ratio of 31.17, and an earnings per share figure of 4.57. The company offers a dividend yield of 71.1%.
Upcoming earnings are scheduled for May 26, 2026, with an estimated EPS of $1.42 and revenue of $1.8 billion, following a recent Q4 2025 report where EPS was $1.59 against an estimate of $1.62, resulting in a 1.6% surprise.
Analyst ratings serve as a professional perspective based on extensive research and financial modelling. While they can provide valuable insights, they are based on assumptions that may not always hold true. Decisions regarding investments should take into account a range of factors, including company fundamentals, industry trends, and individual financial objectives.
Analyst consensus as of December 1, 2025, indicates a Buy rating, with 6 Strong Buy, 10 Buy, and 10 Hold recommendations from a total of 26 analysts. Recent actions include Goldman Sachs initiating coverage with a Buy rating and Morgan Stanley also assigning an Overweight rating.
Such decisions reflect evolving views on Agilent's performance in a competitive landscape, highlighting the importance of continuous assessment in the investment process.